To know you are an idiot, all anyone has to read is you suggesting the media is in bed with Republicans. What a buffoon you are.
this might get the the award for stupidest post EVER. The March outlook will be a disaster. They don't have anything. SOW #2 is not happening. without that, they don't have anything.
IONA ENERGY LTD. (INA-V, $0.61)
Recommendation: Strong Buy; Target: $2.25
Iona Reaches Major Milestone On Closing of Deal and Signoff on $250mm
Borrowing Facility; $60mm Structured Deal with BP Adds an Extra Sweetener
Iona closes $23mm bought deal and obtains $250mm
bank line to fund Huntington & Orlando
The previously announced private placement is now
closed, with INA having raised $23mm while the $250mm
credit facility agreement has also been signed with 3
banks. The bank line is higher than previously discussed
($200mm), with a smaller bank syndicate, and we view
this as demonstrating confidence in Iona’s assets and
ability to carry out development. This is a tremendous
milestone for Iona with the Company set to see first oil at
Huntington (total consideration of $176mm) as early as
April, and Orlando development moving ahead
I can't find the written transcript either, but you can listen to the audio at the company website. The first half of it is just a rehash of the press release, but the Q and A is interesting.
OK, I have a PACER account. Give me the caption of the case, the docket number, and the district the case was filed in (e.g., US District Ct. for the Northern Dist. of Ohio), or as much information as you have. Unless the matter is under seal (in which case, how the [expletive deleted] would you know about it?), that will give ME enough to find the case and the pleadings. Then we can verify your allegation. Put up or shut up, an do it quickly.
The presence of far more mature tablet alternatives such as the iPad has resulted in weak sales of the Surface RT. Its got nothing to do with CloverTrail. CloverTrail has no market presence in tablets which is what it was designed for. Both tablets and phones are dominated by ARM. Windows 8's impact on the existing tablet market has been miniscular. As it stands Intel is nowhere on the mobile map.
There is this guy marketmaker who posts on the AERL. Is he A LIAR? I'm just asking the question because I know a lot of posters on the board think so. I mean I hear there are some people who go short a stock and the bash it endlessly with opened ended questions meant to create fear. Is marketmaker ONE OF THOSE PEOPLE? Heck, I just think the other people on this board need to know this stuff. I'm just writing this for their sake. Because if marketmaker is A LYING SHORT everyone should know that. Know what I mean? Hey, I'm just asking questions here. There is a rumor he uses stories about the government making sure they get rid of any crinimal element in Macau and tries to say it means the whole junket business model is at risk. is he LYING WHEN HE SAYS THAT or just confused? These questions need to be asked on behalf of ignorant investors who marketmaker thinks are too stupid to make decisions on their own.
Getting the picture? Can it be said I called marketmaker a liar? No. Is anyone confused about what my intention is? You shouldn't be.
Now before a certain someone gets his shorts in a bunch remember, I never said you lied and I never said you are short the stock. I'm just protecting the innocent, unsuspecting retail guys. Bully for me.
InsuranceLow.... is a comprehensive car insurance site designed to help serve you with making the best choice you can in picking the most affordable insurance solution that fits your needs. The more you know, the better you are to find the right type of car insurance coverage for you and your family. We thank you for visiting InsuranceLow.,,, and wish you the best of luck in picking the best car insurance solution for you!
Mo, Perhaps the rough road is behind us for awhile now. Glad to see longs get exited about near term catalysts and pending revenue streams. Believing in this company has been liked getting wet towel snapped every day by the bully in the school gym......but the wounds are healing well. Good luck bud, hope this high volume day means we're finally on the radar of investors.
Alcatel-Lucent Names Chief to Lead a Major Downsizing
New York Times - 13 hours ago
BERLIN - Alcatel-Lucent, the struggling French telecommunications equipment maker, on Friday hired a former Vodafone and France Télécom executive, Michel Combes, to lead the company through what might be a major downsizing.
michaelangelo --- you might try reading the NEW YORK TIMES
F.D.A. Approves a New Drug for Advanced Breast Cancer
By ANDREW POLLACK
Published: February 22, 2013
The Food and Drug Administration on Friday approved a new type of drug that combines the widely used breast cancer medicine Herceptin with a powerful toxin to more effectively kill cancer cells while potentially reducing side effects.
Enlarge This Image
Kadcyla, which was known as T-DM1 during its development by Genentech, extended the median survival of women with advanced breast cancer by nearly half a year in a clinical trial.
The drug, which will be called Kadcyla but was known as T-DM1 during its development, extended the median survival of women with advanced breast cancer by nearly half a year in a clinical trial.
Genentech, which developed the drug, said it would cost about $9,800 a month, or $94,000 for a typical course of treatment. That is about twice the price of Herceptin itself, which is also made by Genentech, but it is similar to the price of some other new cancer drugs.
Kadcyla, which the company said could be available within days, is one of the first successful examples of a new class of drugs that link toxins to proteins known as monoclonal antibodies. The antibodies latch onto tumors and deliver the toxic payload. Because the toxin is not activated until it reaches the tumor, healthy cells are spared and some side effects are avoided.
Such medicines, known as antibody-drug conjugates, are a hot area for cancer drug developers, with around two dozen such drugs in clinical trials. Another antibody-drug conjugate, Adcetris, developed by Seattle Genetics, was approved in 2011 as a treatment for two rare types of lymphoma.
The linker and toxin used in Kadcyla were developed by ImmunoGen, based in Waltham, Mass., which will receive royalties on sales of the drug. This is the first approved product for ImmunoGen, which has been working on antibody-drug conjugates for three decades.......
Sentiment: Strong Sell